NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces the Company has entered into a debt settlement agreement with an arm's length creditor (the "Creditor") related to an aggregate of $225,010 outstanding debt (the "Debt") owing for services provided by the Creditor to the Company. In full satisfaction and settlement ...

TRENDING: America's Most Trusted Financial Companies As the market rally continues with major indexes scoring new records this week, several stocks in the elite IBD 50 list of growth names are extended. But for those stocks that have formed bases, breakouts can lead to hefty gains. Apart from artificial intelligence and software stocks, the list has no less than 15 health care names, indicating that the… Related news IBD Videos Get market updates, educational videos, webinars, and stock analysis. Get Starte ...

Inhibrx Biosciences, Inc. (NASDAQ:INBX) operates within the highly competitive biotechnology sector, focusing on the development of protein-based therapeutics aimed at treating cancer and other serious diseases. This industry includes notable competitors such as Keros Therapeutics, Kymera Therapeutics, iTeos Therapeutics, Harmony Biosciences Holdings, and Vaxcyte, all of which are striving to innovate in the treatment space.Analyzing INBX's financial health, the company's Return on Invested Capital (ROIC) i ...

PresentationHey, everyone. Welcome to our next session with Curis. My name is Li Watsek, a biotech analyst here at Cantor. I'm very pleased to have Jim Dentzer, CEO of Curis, with us today. Maybe start, I'll just hand it over to Jim to give us some quick overview.James DentzerPresident, CEO, Secretary, Treasurer & Director Thank you. I appreciate it, and thank you for having me. Yes, the overview of Curis is we're really at an exciting crossroads. So we've got one drug that we're funding. We've got a pretty ...

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells' therapeutic advantages compared to stem cell therapi ...

argenx SE (NASDAQ: ARGX ) is a Dutch biotechnology company specializing in the development of therapeutic antibodies for the treatment of diseases. The company has a strong focus on research and development and has shown strongAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ARGX over the next 72 hours. I wrote ...

argenx SE (NASDAQ: ARGX ) is a Dutch biotechnology company specializing in the development of therapeutic antibodies for the treatment of diseases. The company has a strong focus on research and development and has shown strongAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ARGX over the next 72 hours. I wrote ...

Several biotech stocks made sharp moves in after-hours trading on Thursday, September 11, 2025, driven by clinical updates, strategic pivots, and rebranding efforts. Here's a quick look at what sparked the action.Modular Medical Inc. (MODD) saw a dramatic upswing in its stock price today, climbing 30.68% overnight to $0.9150, following a modest 1.27% gain at market close to $0.7002The rally was sparked by the company's announcement that it had completed a clinical study for its MODD1 insulin pump, a device ...

Not only has the fund performed well, but it has also seen some exciting data, according to YCharts. The fund's price has risen above both its 50 and 200-day simple moving averages (SMAs), historically an indicator of healthy momentum and a buy signal. In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well. With potentially multiple rate cuts on the horizon, then, i ...

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it closed its previously announced underwritten public offering of 7,627,879 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,1 ...